Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of Lenti-D in patients with an inherited brain disorder
RBR-72wbbgRecruiting
- Sponsor
- Blanchard y Asociados
- Start
- Jan 2016
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of elivaldogene autotemcel in lipid metabolism disorder and Inherited brain disorder, sponsored by Blanchard y Asociados. Primary endpoints: Long-term efficacy of Lenti-D and Long-term safety of Lenti-D. Started Jan 2016; status: recruiting.
02
Drugs
elivaldogene autotemcel
03
Conditions
lipid metabolism disorderInherited brain disorder
Beyond the preview
Go deeper on RBR-72wbbg.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-72wbbg.